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1. Introduction & Background 
Quality of care
“I’d kind of probably take part in it… ‘cause think if something
didn’t work on me I know that they’d just like, if I needed to they’d
just put me on something else like in the end…?” (Child 9)
Treatment suitability
“He had inflammation in about 
36 joints… they said… ‘give 
him some kind of aggressive 
treatment’. So that’s what they 
addressed [IV] as - aggressive 
treatment” (Parent 9)
Travel/time
“I work full time…
they’re very 
restricted of what 
time you can have 
off” (Parent 6)
Treatment interactions
“I don't know, would they stop 
the Methotrexate or would 
they just carry it on?”
(Parent 4)
• Participants tended to describe being more willing to
participate at diagnosis than at flare-up. Parents reported
diagnosis to be an intensely emotional time, at which they
would prefer treatment certainty.
• Participants typically reported being less willing to
participate at flare-up. Prior experience of delivery routes
influenced perceptions of future treatment efficacy.
Five overarching themes emerged as key trial concerns:
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• No family appeared in equipoise regarding the delivery
routes, largely due to previous treatment experiences.
• Recruitment of patients with flaring disease to a
future trial will likely be challenging; treatment
preferences were typically experience-based rather
than anticipated.
• A key question clinicians will need to answer is: “If it’s
not worked this time, what makes them think it’s going
to work the second time?” (Parent 6).
• Confidence and reassurance from clinicians regarding
treatment credibility and trial legitimacy could be key
to participation willingness in a future trial.
Intra-articular injection (IA)
• Most children had first-hand experience
(n=13).
• Sporadic relief.
• More suitable for severe joint flares and
cases with few affected joints.
• Immediate effect but trepidation about
anaesthetic.
Methylprednisolone (tablets)
• Most children had first-hand experience
(n=10).
• Often deemed ineffective.
• Less intensive and unsuitable for severe
flares. Convenient but side effects were a
concern.
Intravenous Injection (IV)
• Half of children had first-hand experience.
• More intensive, fast-acting but sporadic in
its relief.
• Those with experience reported facial
puffiness and weight gain.
• Those without experience queried its
suitability for young children.
Intra-muscular Injection (IM)
• Three children had first-hand experience
(all >10 years old).
• Reported and perceived as fast-acting.
• One child said it was painful.
• No reported or perceived side effects.
• Current delivery routes of corticosteroid treatment for
juvenile idiopathic arthritis (JIA) are based on physician
and patient preference, rather than scientific evidence.
• This qualitative study aims to inform the development of
a future trial that will evaluate the most effective routes
and doses of CS. In particular, we explored treatment
preferences, acceptability of randomisation, willingness
to participate, and deliberations regarding outcomes.
• Semi-structured interviews with a purposive sample of
patients and parents (N = 28) recruited via rheumatology
clinics at four UK sites (9 children and 19 parents).
• Eligible families had children aged 1-16 years (although
for children aged 7 years or less only the parents were
interviewed), with recent experience (< 12 months) of CS
treatment and either recent JIA diagnosis or flare.
• Interviews were audio recorded and transcribed. Data
analysis drew on thematic analysis techniques.
Randomisation
“Computers wouldn’t 
[know] what it’s 
doing… whereas a 
person… they’d know 
themself if they’d 
trained for years” 
(Child 12)
About Juvenile IdIopathic Arthritis (JIA)
JIA is a heterogeneous collection of diseases affecting 15,000
children in the UK. Common symptoms include: joint pain, swelling
and stiffness. Corticosteroids (CS) can help to achieve rapid
disease control in children presenting with new or flaring JIA.
